Preconditioning by ultra-low dose of tramadol reduces the severity of tramadol-induced seizure: Contribution of glutamate receptors

Biomed Pharmacother. 2021 Jan:133:111031. doi: 10.1016/j.biopha.2020.111031. Epub 2020 Nov 26.

Abstract

Tramadol, a weak agonist of mu-opioid receptors, causes seizure via several mechanisms. Preconditioning has been purposed to reduce the epileptic seizures in animal models of epilepsy. The preconditioning effect of tramadol on seizure is not studied yet. This study was designed to evaluate the preconditioning effect of ultra-low dose of tramadol on the seizures induced by tramadol at high dose. Furthermore, regarding the critical role of glutamate signaling in the pathogenesis of epilepsy, the effect of preconditioning on some glutamate signaling elements was also examined. Male Wistar rats received tramadol (2 mg/kg, i.p) or normal saline (1 mL/kg, i.p) in preconditioning and control groups, respectively. After 4 days, the challenging tramadol dose (150 mg/kg) was injected to all rats. Epileptic behaviors were recorded during 50 min. The expression of Norbin (as a regulator of metabotropic glutamate receptor 5), Calponin3 (as a regulator of excitatory synaptic markers), NR1 (NMDA receptor subunit 1) and GluR1 (AMPA receptor subunit 1) was measured in hippocampus, prefrontal cortex (PFC) and amygdala. Preconditioning decreased the number and duration of tremors and tonic-clonic seizures. Norbin, Calponin3, NR1 and GluR1 expression were decreased in hippocampus, and preconditioning had no effect on them. In contrast, it increased Norbin expression in PFC and amygdala, and attenuated NR1 and GluR1 upregulation following tramadol at high dose. These findings indicated that preconditioning by ultra-low dose of tramadol protected the animals against seizures following high dose of tramadol mediated, at least in part, by Norbin up regulation, and NR1 and GluR1 down regulation.

Keywords: AMPA; Calponin 3; Glutamate; NMDA; Norbin; Preconditioning; Seizure; Tramadol.

MeSH terms

  • Analgesics, Opioid / administration & dosage*
  • Analgesics, Opioid / toxicity
  • Animals
  • Anticonvulsants / administration & dosage*
  • Anticonvulsants / toxicity
  • Brain / drug effects*
  • Brain / metabolism
  • Brain / physiopathology
  • Calcium-Binding Proteins / genetics
  • Calcium-Binding Proteins / metabolism
  • Calponins
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Down-Regulation
  • Male
  • Microfilament Proteins / genetics
  • Microfilament Proteins / metabolism
  • Neuropeptides / genetics
  • Neuropeptides / metabolism
  • Rats
  • Rats, Wistar
  • Receptors, AMPA / genetics
  • Receptors, AMPA / metabolism*
  • Receptors, N-Methyl-D-Aspartate / genetics
  • Receptors, N-Methyl-D-Aspartate / metabolism*
  • Seizures / chemically induced
  • Seizures / metabolism
  • Seizures / physiopathology
  • Seizures / prevention & control*
  • Severity of Illness Index
  • Tramadol / administration & dosage*
  • Tramadol / toxicity

Substances

  • Analgesics, Opioid
  • Anticonvulsants
  • Calcium-Binding Proteins
  • Microfilament Proteins
  • NMDA receptor A1
  • Neuropeptides
  • Receptors, AMPA
  • Receptors, N-Methyl-D-Aspartate
  • norbin
  • Tramadol
  • glutamate receptor ionotropic, AMPA 1